2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

gastric cancer cell lines

" in MedChemExpress (MCE) Product Catalog:

22

阻害剤およびアゴニスト

3

阻害性抗体

4

天然物

Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-N0255
    alpha-Hederin
    3 Publications Verification

    α-Hederin

    		 Apoptosis Others Cancer
    alpha-Hederin (α-Hederin), a monodesmosidic triterpenoid saponin, exhibits promising antitumor potential against a variety of human cancer cell lines. alpha-Hederin could inhibit the proliferation and induce apoptosis of gastric cancer accompanied by glutathione decrement and reactive oxygen species generation via activating mitochondrial dependent pathway .
    alpha-Hederin
  • HY-156617A
    (αR)-Cyclopropaneacetamide-Exatecan

    SHR169265

    		 ADC Payload Topoisomerase Cancer
    (αR)-Cyclopropaneacetamide-Exatecan (SHR169265) is a DNA Topoisomerase I inhibitor with enhanced membrane permeability (with an IC50 of 1.34 μM against the human DNA Topoisomerase I). (αR)-Cyclopropaneacetamide-Exatecan exerts cytotoxic effects by inhibiting the enzymatic activity of Topoisomerase I, and this anticancer effect is independent of the expression level of HER2. (αR)-Cyclopropaneacetamide-Exatecan is an ADC Cytotoxin derived from Exatecan (HY-13631), which can be used in research related to advanced cancers such as breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer .
    (αR)-Cyclopropaneacetamide-Exatecan
  • HY-P991728
    Zarutatug

    TORL-3-600 antibody

    		 Cadherin ADC Antibody Cancer
    Zarutatug (TORL-3-600 antibody) is an IgG1κ humanized antibody targeting cadherin 17 (CDH17). It selectively binds to cell-surface CDH17, triggering endocytosis and trafficking to lysosomes. Zarutatug can be used to construct ADCs, such as TORL-3-600 .
    Zarutatug
  • HY-156418
    KY386

    		DNA/RNA Synthesis Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Cancer
    KY386 is a DHX33 helicase inhibitor with an IC50 of 0.019 μM. KY386 inhibits the cell viability of various cancer cells. KY386 induces ferroptosis in cancer cells, and induces apoptosis in some cancer cell lines. KY386 increases the intracellular levels of ROS, LPO and Fe 2+, and decreases the level of GSH in cancer cells . KY386 inhibits the growth of gastric cancer and colon cancer xenografts in nude mice. KY386 is applicable to the related research on liver cancer, lung cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, leukemia, renal cancer, prostate cancer, esophageal cancer, cervical cancer, brain cancer (glioblastoma) and melanoma .
    KY386
  • HY-100555
    CH5138303

    		HSP Infection Cancer
    CH5138303 is a potent and orally active Hsp90 inhibitor. CH5138303 shows high binding affinity for N-terminal Hsp90α, with Kd of 0.52 nM. CH5138303 shows potent anti-proliferative activity against human cancer cell lines (HCT116 and NCI-N87), with IC50 values of 0.098 and 0.066 μM, respectively. CH5138303 shows high oral bioavailability in mice (F=44.0%). CH5138303 shows potent antitumor efficacy in a human NCI-N87 gastric cancer xenograft model .
    CH5138303
  • HY-176798
    NCI-006

    		Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis Cancer
    NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
    NCI-006
  • HY-178238
    LD2-3

    		ADC Payload Topoisomerase Cancer
    LD2-3 is a cytotoxic compound derived from Exatecan (HY-13631), designed to be conjugated with anti-FGFR2b or anti-CEA antibodies to form intact antibody-drug conjugate (ADC) molecules. LD2-3 exhibits a remarkable bystander killing effect: it not only effectively kills FGFR2b-positive tumor cells, but also eliminates surrounding FGFR2b-negative cells in co-culture and mixed tumor xenograft models, thereby inducing complete tumor regression. LD2-3 can be used for anti-tumor research in relevant fields such as gastric cancer and lung cancer .
    LD2-3
  • HY-106588
    Heptaplatin

    SKI 2053R

    		 DNA Alkylator/Crosslinker Cancer
    Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles .
    Heptaplatin
  • HY-117085
    Lobaric acid

    		Phosphatase TMV Lipoxygenase Cancer
    Lobaric acid is a depsipeptide metabolite isolated from Stereocaulon lichen with antioxidant, antiproliferative, antiviral and enzyme inhibitory activities. Lobaric acid scavenges superoxide free radicals (IC50=97.9 μM) and inhibits cancer cell proliferation (EC50 of 15.2-63.9 μg/mL against leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic and lung cancer cell lines). Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC50=0.87 μM for human recombinant enzyme) and 12(S)-HETE produced by 12(S)-lipoxygenase (IC50=28.5 μM). Lobaric acid (250 μM) also reduced pathological changes in tobacco leaves infected with tobacco mosaic virus (TMV).
    Lobaric acid
  • HY-W741940
    Evomonoside

    		Others Cardiovascular Disease Cancer
    Evomonoside is a type of cardiac glycoside compound. Evomonoside exhibits significant in vitro anticancer activity, especially having nanomolar inhibitory concentrations against gastric cancer cell lines. Evomonoside has typical cardiac toxicity risks, including arrhythmias and conduction abnormalities. Evomonoside can be used for research on gastric cancer .
    Evomonoside
  • HY-175733
    CQ3196

    		RIO Kinase Apoptosis Cancer
    CQ3196 is an orally active RIOK2 inhibitor with a Kd of 14 nM. CQ3196 effectively inhibits the ATPase activity of RIOK2, with an IC50 value of 72 nM. CQ3196 inhibits cell proliferation and colony formation in gastric cancer cell lines. CQ3196 induces cell apoptosis in HGC-27 and AGS cells. CQ3196 suppresses downstream signal pathway of RIOK2. CQ3196 reduces phosphorylation of mTOR and AKT. CQ3196 modulates ribosome function and protein synthesis. CQ3196 inhibits tumor growth and can be used for gastric cancer invtro and invivo research .
    CQ3196
  • HY-178112
    CDK2-IN-47

    		CDK Apoptosis Cancer
    CDK2-IN-47 is a potent CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer .
    CDK2-IN-47
  • HY-176283
    Tubulin/LSD1-IN-1

    		Microtubule/Tubulin Histone Demethylase Apoptosis Wee1 Bcl-2 Family Caspase Cancer
    Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and LSD1 (IC50 = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells .
    Tubulin/LSD1-IN-1
  • HY-168044
    ALKBH1-IN-3

    		AMPK Cancer
    ALKBH1-IN-3 is a potent DNA N6-methyladenine (6mA) demethylase ALKBH1 inhibitor. ALKBH1-IN-3 increases the abundance of 6mA, inhibits cell viability and upregulates the AMP-activated protein kinase (AMPK) signaling pathway in gastric cancer cell lines HGC27 and AGS. ALKBH1-IN-3 is promising for research of cancers, including gastric cancer .
    ALKBH1-IN-3
  • HY-W395613
    TY-011

    		Aurora Kinase Cancer
    TY-011 is an Aurora A/B kinase inhibitor. TY-011 induces abnormal microtubule-kinetochore attachment, leading to DNA damage and apoptosis (Apoptosis) in human gastric cancer cells, and ultimately inhibits cancer cell proliferation, with an IC50 value ranging from 0.11 to 4.49 μM in human gastric cancer cell lines. TY-011 has potential applications in gastric cancer research .
    TY-011
  • HY-164411
    KRC-00715

    		c-Met/HGFR Cancer
    KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models .
    KRC-00715
  • HY-111007
    CH5015765

    		HSP Cancer
    CH5015765 is an orally available Hsp90 inhibitor bound to the N-terminal ATP binding site, with a dissociation constant of 3.4 nM, CH5015765 exerts antiproliferative activity against human cancer cell lines, with IC50 values of 0.46 μM for HCT116 colorectal cancer cells and 0.57 μM for NCI-N87 gastric cancer cells. CH5015765 can be used for the study of cancer .
    CH5015765
  • HY-115885
    XP5

    		HDAC Inflammation/Immunology Cancer
    XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma .
    XP5
  • HY-N0255R
    alpha-Hederin (Standard)

    α-Hederin (Standard)

    		 Reference Standards Apoptosis Others
    alpha-Hederin (Standard) is the analytical standard of alpha-Hederin. This product is intended for research and analytical applications. alpha-Hederin (α-Hederin), a monodesmosidic triterpenoid saponin, exhibits promising antitumor potential against a variety of human cancer cell lines. alpha-Hederin could inhibit the proliferation and induce apoptosis of gastric cancer accompanied by glutathione decrement and reactive oxygen species generation via activating mitochondrial dependent pathway .
    alpha-Hederin (Standard)
  • HY-N3626
    Coronalolide

    		Others Cancer
    Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC50 values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .
    Coronalolide
  • HY-P991896
    AT1412

    AT14-012

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
    AT1412
  • HY-164717
    FORX-428

    		Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    FORX-428 is a selective and orally active Poly (ADP-ribose) glycohydrolase (PARG) inhibitor. FORX-428 exhibits strong and reversible binding to the catalytic domain of human PARG, and thereby inhibits PARG´s enzymatic activity. FORX-428 leads to the excessive accumulation of PAR chains and activates DNA damage and replication stress responses. FORX-428 selectively inhibits the proliferation of various cancer cell lines, including breast, ovarian, and gastric cancer .
    FORX-428

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: